BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Mayfield J, Miller VA, Stephens PJ, Ross JS, Ali SM. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol 2015;8:66. [PMID: 26062823 DOI: 10.1186/s13045-015-0160-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Liu W, Liu HJ, Wang WY, Tang Y, Zhao S, Zhang WY, Yan JQ, Liu WP. Multisystem ALK-positive histiocytosis: a multi-case study and literature review. Orphanet J Rare Dis 2023;18:53. [PMID: 36915094 DOI: 10.1186/s13023-023-02649-x] [Reference Citation Analysis]
2 Zhang L, Luan L, Shen L, Xue R, Huang J, Su J, Huang Y, Xu Y, Wang X, Shao Y, Ji Y, Xu C, Hou Y. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review. Virchows Arch 2023;482:567-80. [PMID: 36624188 DOI: 10.1007/s00428-022-03457-7] [Reference Citation Analysis]
3 Devins KM, Samore W, Nielsen GP, Deshpande V, Oliva E. Leiomyoma-like Morphology in Metastatic Uterine Inflammatory Myofibroblastic Tumors. Mod Pathol 2023;36:100143. [PMID: 36806735 DOI: 10.1016/j.modpat.2023.100143] [Reference Citation Analysis]
4 Ladwig NR, Bean GR, Pekmezci M, Boscardin J, Joseph NM, Therrien N, Sangoi AR, Piening B, Rajamanickam V, Galvin M, Bernard B, Zaloudek C, Rabban JT, Garg K, Umetsu SE. Uterine Inflammatory Myofibroblastic Tumors: Proposed Risk Stratification Model Using Integrated Clinicopathologic and Molecular Analysis. Am J Surg Pathol 2023;47:157-71. [PMID: 36344483 DOI: 10.1097/PAS.0000000000001987] [Reference Citation Analysis]
5 Karpathiou G, Devouassoux-Shisheboran M, Stolnicu S, Chauleur C, Péoc'h M. Uterine inflammatory myofibroblastic tumor. Pathol Res Pract 2023;242:154335. [PMID: 36706588 DOI: 10.1016/j.prp.2023.154335] [Reference Citation Analysis]
6 Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 2023;29:401-9. [PMID: 36288393 DOI: 10.1158/1078-0432.CCR-22-2509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bowman CJ, Medeiros F, Fadare O, Sangoi AR, Horvai AE, Devine WP, McCluggage WG, Rabban JT. ALK Immunoexpression is Specific for Inflammatory Myofibroblastic Tumor Among Vulvovaginal Mesenchymal Neoplasms. Int J Gynecol Pathol 2023;42:1-10. [PMID: 35180768 DOI: 10.1097/PGP.0000000000000858] [Reference Citation Analysis]
8 Riskjell AI, Mäkinen V, Paulsen BS, Aggerholm-pedersen N. Targeted treatment of soft-tissue sarcoma.. [DOI: 10.21203/rs.3.rs-1854280/v1] [Reference Citation Analysis]
9 He W, Ji X, Song C, Song S, Liu L. Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare GCC2-ALK fusion. Front Oncol 2022;12:934887. [DOI: 10.3389/fonc.2022.934887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Durham C, Clemons M, Alias A, Konduri K. Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review. Cureus 2022. [DOI: 10.7759/cureus.27223] [Reference Citation Analysis]
11 Gao F, Gao F, Wu H, Lu J, Xu Y, Zhao Y. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements. Thorac Cancer 2022. [PMID: 35212154 DOI: 10.1111/1759-7714.14345] [Reference Citation Analysis]
12 Ng ZY, Khaing CT, Aggarwal I. Inflammatory myofibroblastic tumor: an under recognized differential of uterine mesenchymal tumors. Int J Gynecol Cancer 2022;32:212-3. [DOI: 10.1136/ijgc-2021-003247] [Reference Citation Analysis]
13 Barreto-Coelho P, Rosenberg A, Subhawong T, Costa P, Espejo-Freire AP, Bialick S, Jonczak E, Trent JC, D'Amato GZ. Treatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report. JCO Precis Oncol 2022;6:e2100336. [PMID: 35108034 DOI: 10.1200/PO.21.00336] [Reference Citation Analysis]
14 Chiang S. Mesenchymal Tumors, Pathology of the Uterine Corpus. Encyclopedia of Pathology 2022. [DOI: 10.1007/978-3-319-28845-1_5626-1] [Reference Citation Analysis]
15 López de Sa A, Pascual A, Garcia Santos J, Mendez R, Bellon M, Ramirez M, Matute F, Del Arco C, Manzano A, Coronado P, Casado A, Marquina G. Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report. World J Surg Oncol 2021;19:331. [PMID: 34801049 DOI: 10.1186/s12957-021-02438-5] [Reference Citation Analysis]
16 Wu J, Hu Y, Abdihamid O, Huang G, Xiao S, Li B. Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy. Front Oncol 2021;11:684865. [PMID: 34722239 DOI: 10.3389/fonc.2021.684865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sanaya SZ, Matsneva IA, Redkina NA, Telezhnikova IM, Magnaeva AS, Tregubova AV, Asaturova AV, Kometova VV. [Immunohistochemical and molecular diagnosis of inflammatory myofibroblastic tumor of the uterus: a literature review and a clinical case]. Arkh Patol 2021;83:43-8. [PMID: 34609804 DOI: 10.17116/patol20218305143] [Reference Citation Analysis]
18 Chen T, Wang Y, Goetz L, Corey Z, Dougher MC, Smith JD, Fox EJ, Freiberg AS, Flemming D, Fanburg-Smith JC. Novel fusion sarcomas including targetable NTRK and ALK. Ann Diagn Pathol 2021;54:151800. [PMID: 34464935 DOI: 10.1016/j.anndiagpath.2021.151800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Wang B, Chen R, Wang C, Guo J, Yuan M, Chen H, Xia X, Zhong D. Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients. Hum Pathol 2021;114:90-8. [PMID: 34019866 DOI: 10.1016/j.humpath.2021.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther 2021;14:3037-49. [PMID: 33994796 DOI: 10.2147/OTT.S291801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Panagopoulos I, Heim S. Interstitial Deletions Generating Fusion Genes. Cancer Genomics Proteomics 2021;18:167-96. [PMID: 33893073 DOI: 10.21873/cgp.20251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Tarantino P, Mazzarella L, Marra A, Trapani D, Curigliano G. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treat Rev 2021;94:102169. [PMID: 33652262 DOI: 10.1016/j.ctrv.2021.102169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Walsh EM, Xing D, Lippitt MH, Fader AN, Wethington SL, Meyer CF, Gaillard SL. Molecular Tumor Board Guides Successful Treatment of a Rare, Locally Aggressive, Uterine Mesenchymal Neoplasm. JCO Precis Oncol 2021;5:PO. [PMID: 34250413 DOI: 10.1200/PO.20.00189] [Reference Citation Analysis]
24 Chiang S. Recent advances in smooth muscle tumors with PGR and PLAG1 gene fusions and myofibroblastic uterine neoplasms. Genes Chromosomes Cancer 2021;60:138-46. [PMID: 33230916 DOI: 10.1002/gcc.22920] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Parra-Herran C. ALK Immunohistochemistry and Molecular Analysis in Uterine Inflammatory Myofibroblastic Tumor: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. Int J Gynecol Pathol 2021;40:28-31. [PMID: 33290353 DOI: 10.1097/PGP.0000000000000704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
26 Devereaux KA, Fitzpatrick MB, Hartinger S, Jones C, Kunder CA, Longacre TA. Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions. Am J Surg Pathol 2020;44:970-81. [PMID: 32271187 DOI: 10.1097/PAS.0000000000001481] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
27 Zarei S, Abdul-karim FW, Chase DM, Astbury C, Policarpio-nicolas MLC. Uterine Inflammatory Myofibroblastic Tumor Showing an Atypical ALK Signal Pattern by FISH and DES-ALK Fusion by RNA Sequencing: A Case Report. International Journal of Gynecological Pathology 2020;39:152-6. [DOI: 10.1097/pgp.0000000000000588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
28 Devereaux KA, Schoolmeester JK. Smooth Muscle Tumors of the Female Genital Tract. Surg Pathol Clin 2019;12:397-455. [PMID: 31097110 DOI: 10.1016/j.path.2019.02.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
29 Xu B, Chen H, Que Y, Xiao W, Zeng M, Zhang X. ALKATI interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma. Oncogene 2020;39:151-63. [DOI: 10.1038/s41388-019-0973-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
30 Wang K, Guo R, Siegal GP, Wei S. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification. Pathol Res Pract 2019;215:152535. [PMID: 31326196 DOI: 10.1016/j.prp.2019.152535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Oliva E, Zaloudek CJ, Soslow RA. Mesenchymal Tumors of the Uterus. In: Kurman RJ, Hedrick Ellenson L, Ronnett BM, editors. Blaustein's Pathology of the Female Genital Tract. Cham: Springer International Publishing; 2019. pp. 535-647. [DOI: 10.1007/978-3-319-46334-6_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Devereaux KA, Kunder CA, Longacre TA. ALK-rearranged Tumors Are Highly Enriched in the STUMP Subcategory of Uterine Tumors. American Journal of Surgical Pathology 2019;43:64-74. [DOI: 10.1097/pas.0000000000001083] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
33 Howitt BE, Nucci MR. Uterine Mesenchymal Lesions. Gynecologic and Obstetric Pathology, Volume 2 2019. [DOI: 10.1007/978-981-13-3019-3_1] [Reference Citation Analysis]
34 Ogata M, Hatachi Y, Ogata T, Satake H, Imai Y, Yasui H. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation. Intern Med 2019;58:1029-32. [PMID: 30449794 DOI: 10.2169/internalmedicine.1640-18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
35 Mohammad N, Haimes JD, Mishkin S, Kudlow BA, Leong MY, Chew SH, Koay E, Whitehouse A, Cope N, Ali RH, Köbel M, Stewart CJ, Mccluggage WG, Lee C. ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus. American Journal of Surgical Pathology 2018;42:1353-9. [DOI: 10.1097/pas.0000000000001120] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
36 Ptáková N, Miesbauerová M, Kosťun J, Grossmann P, Šidlová H, Pavelka J, Presl J, Alaghehbandan R, Bouda J, Ondič O. Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors. Virchows Arch 2018;473:583-90. [DOI: 10.1007/s00428-018-2428-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
37 Holzmann C, Saager C, Mechtersheimer G, Koczan D, Helmke BM, Bullerdiek J. Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with ALK rearrangement and loss of 14q. Oncotarget 2018;9:27595-604. [PMID: 29963223 DOI: 10.18632/oncotarget.25137] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
38 Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 2017;8:39254-67. [PMID: 28424409 DOI: 10.18632/oncotarget.16845] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 9.4] [Reference Citation Analysis]
39 Kube S, Vokuhl C, Dantonello T, Scheer M, Hallmen E, Feuchtgruber S, Escherich G, Niggli F, Kuehnle I, von Kalle T, Bielack S, Klingebiel T, Koscielniak E. Inflammatory myofibroblastic tumors-A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 2018;65:e27012. [PMID: 29480552 DOI: 10.1002/pbc.27012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
40 Vargas-Madueno F, Gould E, Valor R, Ngo N, Zhang L, Villalona-Calero MA. EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors. Oncologist 2018;23:1127-32. [PMID: 29739898 DOI: 10.1634/theoncologist.2018-0014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
41 Dickson BC, Swanson D, Charames GS, Fletcher CD, Hornick JL. Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases. Mod Pathol 2018;31:753-62. [PMID: 29327718 DOI: 10.1038/modpathol.2017.191] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
42 Theilen TM, Soerensen J, Bochennek K, Becker M, Schwabe D, Rolle U, Klingebiel T, Lehrnbecher T. Crizotinib in ALK(+) inflammatory myofibroblastic tumors-Current experience and future perspectives. Pediatr Blood Cancer 2018;65. [PMID: 29286567 DOI: 10.1002/pbc.26920] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
43 Kesrouani C, Zemoura L, Laé M. [A peculiar intra-uterine lesion: Inflammatory myofibroblastic tumor (IMT)]. Ann Pathol 2018;38:143-6. [PMID: 29397221 DOI: 10.1016/j.annpat.2017.12.003] [Reference Citation Analysis]
44 Subbiah V, Kurzrock R. Challenging Standard-of-Care Paradigms in the Precision Oncology Era. Trends Cancer 2018;4:101-9. [PMID: 29458960 DOI: 10.1016/j.trecan.2017.12.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
45 Ambati SR, Slotkin EK, Chow-Maneval E, Basu EM. Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions. JCO Precis Oncol 2018;2:https. [PMID: 31763577 DOI: 10.1200/PO.18.00095] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
46 Oliva E, Zaloudek CJ, Soslow RA. Mesenchymal Tumors of the Uterus. Blaustein's Pathology of the Female Genital Tract 2018. [DOI: 10.1007/978-1-4614-3165-7_10-2] [Reference Citation Analysis]
47 Mandato VD, Valli R, Mastrofilippo V, Bisagni A, Aguzzoli L, La Sala GB. Uterine inflammatory myofibroblastic tumor: more common than expected: Case report and review. Medicine (Baltimore) 2017;96:e8974. [PMID: 29310405 DOI: 10.1097/MD.0000000000008974] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
48 Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 2017;7:15963. [PMID: 29162825 DOI: 10.1038/s41598-017-13114-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
49 Tsakiri K, Kotoula V, Lakis S, Müller J, Fostira F, Bobos M, Hytiroglou P, Fountzilas G. Crizotinib Failure in a TPM4-ALK –Rearranged Inflammatory Myofibroblastic Tumor With an Emerging ALK Kinase Domain Mutation. JCO Precision Oncology 2017. [DOI: 10.1200/po.17.00015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
50 Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Miller VA, Stephens PJ, Gay LM. ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. Oncologist 2017;22:1444-50. [PMID: 29079636 DOI: 10.1634/theoncologist.2016-0488] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
51 Groisberg R, Roszik J, Conley A, Patel SR, Subbiah V. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Curr Oncol Rep 2017;19. [DOI: 10.1007/s11912-017-0641-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
52 Vendrell JA, Taviaux S, Béganton B, Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V, Coopman P, Mazières J, Costes V, Pujol JL, Brousset P, Rouquette I, Solassol J. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep 2017;7:12510. [PMID: 28970558 DOI: 10.1038/s41598-017-12679-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 10.3] [Reference Citation Analysis]
53 Pickett JL, Chou A, Andrici JA, Clarkson A, Sioson L, Sheen A, Reagh J, Najdawi F, Kim Y, Riley D, Maidens J, Nevell D, McIlroy K, Valmadre S, Gard G, Hogg R, Turchini J, Robertson G, Friedlander M, Gill AJ. Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required. Am J Surg Pathol 2017;41:1433-42. [PMID: 28731868 DOI: 10.1097/PAS.0000000000000909] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
54 Bennett JA, Nardi V, Rouzbahman M, Morales-oyarvide V, Nielsen GP, Oliva E. Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum. Modern Pathology 2017;30:1489-1503. [DOI: 10.1038/modpathol.2017.69] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 13.8] [Reference Citation Analysis]
55 Haimes JD, Stewart CJR, Kudlow BA, Culver BP, Meng B, Koay E, Whitehouse A, Cope N, Lee JC, Ng T, McCluggage WG, Lee CH. Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1. Am J Surg Pathol 2017;41:773-80. [PMID: 28490045 DOI: 10.1097/PAS.0000000000000801] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 14.0] [Reference Citation Analysis]
56 Rosenzweig M, Ali SM, Wong V, Schrock AB, Laetsch TW, Ahrens W, Heilmann A, Morley S, Chudnovsky Y, Erlich RL, Wang K, Stephens PJ, Ross JS, Miller VA, Oesterheld J. A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion. Pediatr Blood Cancer 2017;64. [PMID: 28028925 DOI: 10.1002/pbc.26377] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
57 Subbiah V, Kurzrock R. Debunking the Delusion That Precision Oncology Is an Illusion. Oncologist 2017;22:881-2. [PMID: 28550030 DOI: 10.1634/theoncologist.2017-0040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
58 Jiang Q, Tong HX, Hou YY, Zhang Y, Li JL, Zhou YH, Xu J, Wang JY, Lu WQ. Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma. Orphanet J Rare Dis 2017;12:97. [PMID: 28535796 DOI: 10.1186/s13023-017-0647-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
59 Shimada Y, Kohno T, Ueno H, Ino Y, Hayashi H, Nakaoku T, Sakamoto Y, Kondo S, Morizane C, Shimada K, Okusaka T, Hiraoka N. An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Oncologist 2017;22:158-64. [PMID: 28167572 DOI: 10.1634/theoncologist.2016-0194] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
60 Lee JC, Li CF, Huang HY, Zhu MJ, Mariño-Enríquez A, Lee CT, Ou WB, Hornick JL, Fletcher JA. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol 2017;241:316-23. [PMID: 27874193 DOI: 10.1002/path.4836] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
61 Tateishi Y, Okudela K, Kawai S, Suzuki T, Umeda S, Matsumura M, Kioi M, Ohashi K. Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report. Diagn Pathol 2016;11:132. [PMID: 27846861 DOI: 10.1186/s13000-016-0586-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
62 Subbiah V, Holmes O, Gowen K, Spritz D, Amini B, Wang WL, Schrock AB, Meric-Bernstam F, Zinner R, Piha-Paul S, Zarzour M, Elvin JA, Erlich RL, Stockman DL, Vergilio JA, Suh JH, Stephens PJ, Miller V, Ross JS, Ali SM. Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology 2016;91:348-53. [PMID: 27764830 DOI: 10.1159/000449204] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
63 Gao X, Sholl LM, Nishino M, Heng JC, Jänne PA, Oxnard GR. Clinical Implications of Variant ALK FISH Rearrangement Patterns. J Thorac Oncol 2015;10:1648-52. [PMID: 26536196 DOI: 10.1097/JTO.0000000000000665] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
64 McDermott M. Inflammatory myofibroblastic tumour. Semin Diagn Pathol 2016:S0740-2570(16)30066-1. [PMID: 28029513 DOI: 10.1053/j.semdp.2016.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
65 Parham DM. Immunohistochemical Markers of Soft Tissue Tumors: Pathologic Diagnosis, Genetic Contributions, and Therapeutic Options. Anal Chem Insights 2015;10:1-10. [PMID: 26549970 DOI: 10.4137/ACI.S32730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
66 Mandelker D, Dal Cin P, Jacene HA, Armand P, Stone RM, Lindeman NI. Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol 2015;4:30. [PMID: 26457233 DOI: 10.1186/s40164-015-0026-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]